Skip to main content

What the FDA labels say about taking them together

Levodopa and olanzapine/samidorphan l-malate

Olanzapine/samidorphan l-malate's FDA label of January 31, 2026 names levodopa in its drug interactions section; the levodopa label PlainMeds reads does not name olanzapine/samidorphan l-malate. The olanzapine/samidorphan l-malate label: “Monitor blood pressure. Levodopa and Dopamine Agonists: Not recommended.”

Check it at the source: the levodopa FDA label on DailyMed (effective July 20, 2026, Merz Pharmaceuticals, LLC); the olanzapine/samidorphan l-malate FDA label on DailyMed (effective January 31, 2026, Alkermes, Inc.).

What does the levodopa label say about olanzapine/samidorphan l-malate?

Levodopa's label (effective July 20, 2026) does not name olanzapine/samidorphan l-malate in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Inbrija), Merz Pharmaceuticals, LLC, effective July 20, 2026 (SPL set 077c0f39-a3a2-4b2b-a184-09131889dcfb), via openFDA; the full label on DailyMed

What does the olanzapine/samidorphan l-malate label say about levodopa?

Olanzapine/samidorphan l-malate label, drug interactions

Monitor blood pressure. ( 7.2 ) Levodopa and Dopamine Agonists: Not recommended.

Source: FDA drug label (LYBALVI), Alkermes, Inc., effective January 31, 2026 (SPL set 32ffddd1-4e2b-45d9-9b36-bb730167ec80), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Levodopa generic labelers
0Olanzapine/samidorphan l-malate generic labelers
LevodopaOlanzapine/samidorphan l-malate
Labeled forParkinson's diseasen/a
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$55.10 per tablet 10-10 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?